Inhibitor Therapeutics (Inhibitor Therapeutics) GF Score : 0/100 (As of Apr. 30, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics GF Score?

Inhibitor Therapeutics has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Inhibitor Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Inhibitor Therapeutics (OTCPK:INTI) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Inhibitor Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 West Platt Street, Suite 200, Tampa, FL, USA, 33606-2173

Website

https://www.inhibitortx.com

Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.

Executives

Black Robe Capital Llc	10 percent owner	900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii	10 percent owner	1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman	director, 10 percent owner	1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii	10 percent owner	C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc	10 percent owner	12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez	director	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty	10 percent owner, officer: See Remarks	C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara	officer: CFO and Treasurer	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie	director	4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin	director	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab	director, officer: Chairman of the Board	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606